Lexicon Pharmaceuticals, Inc. (LXRX)
-NasdaqGS 2.16 
0.02(0.92%) 11:52AM EDT - Nasdaq Real Time Price
| Prev Close: | 2.18 |
|---|
| Open: | 2.12 |
|---|
| Bid: | 2.15 x 1900 |
|---|
| Ask: | 2.16 x 600 |
|---|
| 1y Target Est: | 3.00 |
|---|
| Beta: | 2.34 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 2.08 - 2.18 |
|---|
| 52wk Range: | 1.50 - 3.28 |
|---|
| Volume: | 339,434 |
|---|
| Avg Vol (3m): | 759,636 |
|---|
| Market Cap: | 1.11B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.21 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- LEXICON PHARMACEUTICALS, INC./DE FinancialsEDGAR Online Financials(Fri, May 17)
- Lexicon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)at Seeking Alpha(Thu, May 16)
- Lexicon To Present At The Bank of America Merrill Lynch Healthcare ConferencePR Newswire(Mon, May 13)
- Lexicon Pharmaceuticals Earnings Call Nuggets: Partnership Talks Update and Carcinoid Enrollmentat Wall St. Cheat Sheet(Sun, May 12)
- Lexicon Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, May 10)
- Q1 2013 Lexicon Pharmaceuticals Inc. Earnings Release - Before Market OpenCCBN(Fri, May 10)
- Lexicon Pharmaceuticals advances LX4211 in type 1 diabetes Phase 2 trialtheflyonthewall.com(Fri, May 10)
- Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 TrialPR Newswire(Fri, May 10)
- Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial ResultsPR Newswire(Fri, May 10)
- LEXICON PHARMACEUTICALS, INC./DE Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemeEDGAR Online(Fri, May 10)
- LEXICON PHARMACEUTICALS, INC./DE Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Thu, May 9)
- Lexicon to Report First Quarter Financial Results on May 10, 2013PR Newswire(Fri, May 3)
- No News Becoming Bad News For Lexicon Pharmaceuticalsat Seeking Alpha(Tue, Apr 30)
- Lexicon Pharma Falls on Concerns Raised by Merck-Pfizer Diabetes Partnershipat TheStreet(Mon, Apr 29)
- FDA Loosening Restrictions and Companies More Diligent in Producing Data the FDA Wants: An Expert Analyst Discusses Drivers in the Favorable Regulatory Environment with The Wall Street TranscriptWall Street Transcript(Mon, Apr 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 973.36 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.17 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.03 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 0.51 |
|---|
Business Summary
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has comple...
View More